Provide feedbackProvide feedback

Home :: Pediatrics :: Pediatrics Conferences :: AACAP 54th Annual Meeting

American Academy of Child & Adolescent Psychiatry

AACAP 54th Annual Meeting

October 23-28, 2007Boston, MA
VerusMed is an independent news organization and is not affiliated with the American Academy of Child & Adolescent Psychiatry

MTA Cooperative Group uses 8-year MTA follow-up data to assess long-term outcomes in children with ADHD

Monday, October 29, 2007 | Comments

Initial data from the Multimodal Treatment Study of Children with ADHD (MTA) provided information about the efficacy of different treatments and treatment combinations in pediatric attention-deficit/hyperactivity disorder. Now, with 8-year follow-up data available, the MTA offers insight into the long-term outcomes of ADHD, including ...[more] Locked

Stigma associated with ADHD prevalent, may affect receptivity to treatment

Friday, October 26, 2007 | Comments

The stigma surrounding attention-deficit/hyperactivity disorder is prevalent and may influence adolescent and caregiver treatment decisions, but clinicians can use this information to select the most appropriate treatment plan, a panel advised.

Several of the panel speakers focused on ADHD-related stigma and presented ...[more] Locked

ADHD, medication use in children associated with emotional strain, poor health status among caregivers

Monday, October 29, 2007 | Comments

Caregivers of children with attention-deficit/hyperactivity disorder--especially those of children who are taking drug therapy--experience significantly more emotional strain and poorer physical and mental health status than do caregivers of children without ADHD, a study found.

For this investigation, 2,036 caregivers ...[more] Locked

Stigma associated with ADHD prevalent, may affect receptivity to treatment

Friday, October 26, 2007 | Comments

The stigma surrounding attention-deficit/hyperactivity disorder is prevalent and may influence adolescent and caregiver treatment decisions, but clinicians can use this information to select the most appropriate treatment plan, a panel advised.

Several of the panel speakers focused on ADHD-related stigma and presented ...[more] Locked

MTA Cooperative Group uses 8-year MTA follow-up data to assess long-term outcomes in children with ADHD

Monday, October 29, 2007 | Comments

Initial data from the Multimodal Treatment Study of Children with ADHD (MTA) provided information about the efficacy of different treatments and treatment combinations in pediatric attention-deficit/hyperactivity disorder. Now, with 8-year follow-up data available, the MTA offers insight into the long-term outcomes of ADHD, including ...[more] Locked

ADHD, medication use in children associated with emotional strain, poor health status among caregivers

Monday, October 29, 2007 | Comments

Caregivers of children with attention-deficit/hyperactivity disorder--especially those of children who are taking drug therapy--experience significantly more emotional strain and poorer physical and mental health status than do caregivers of children without ADHD, a study found.

For this investigation, 2,036 caregivers ...[more] Locked

Triple-bead MAS improves ADHD symptoms in adults, data indicate

Tuesday, October 30, 2007 | Comments

Triple-bead mixed amphetamine salts (MAS), an investigational formulation of MAS designed for once-daily dosing, significantly improves symptoms of attention-deficit/hyperactivity disorder in adults, according to findings from 2 Phase III trials.

The double-blind trials enrolled adults aged 18 to 55 years with ADHD. In ...[more] Locked

Lisdexamfetamine beneficial for adults with ADHD, new data indicate

Monday, October 29, 2007 | Comments

Adult patients with attention-deficit/hyperactivity disorder demonstrate significant improvements in symptom control within a week of taking lisdexamfetamine, Phase III trial data show.

The double-blind, dose-escalation study included 420 adults aged 18 to 55 years who met DSM-IV-TR criteria for ADHD and whose diagnosis ...[more] Locked

Triple-bead mixed amphetamine salts improves ADHD symptoms in adolescents during 16-hour treatment period, Phase II data indicate

Friday, October 26, 2007 | Comments

Once-daily dosing with triple-bead mixed amphetamine salts (triple-bead MAS), an investigational treatment for attention-deficit/hyperactivity disorder, seems to improve ADHD symptoms in adolescents relative to placebo and demonstrates efficacy throughout a 16-hour treatment period, according to Phase II findings.

...[more] Locked

Triple-bead MAS improves ADHD symptoms in adults, data indicate

Tuesday, October 30, 2007 | Comments

Triple-bead mixed amphetamine salts (MAS), an investigational formulation of MAS designed for once-daily dosing, significantly improves symptoms of attention-deficit/hyperactivity disorder in adults, according to findings from 2 Phase III trials.

The double-blind trials enrolled adults aged 18 to 55 years with ADHD. In ...[more] Locked

Lisdexamfetamine beneficial for adults with ADHD, new data indicate

Monday, October 29, 2007 | Comments

Adult patients with attention-deficit/hyperactivity disorder demonstrate significant improvements in symptom control within a week of taking lisdexamfetamine, Phase III trial data show.

The double-blind, dose-escalation study included 420 adults aged 18 to 55 years who met DSM-IV-TR criteria for ADHD and whose diagnosis ...[more] Locked

Triple-bead mixed amphetamine salts improves ADHD symptoms in adolescents during 16-hour treatment period, Phase II data indicate

Friday, October 26, 2007 | Comments

Once-daily dosing with triple-bead mixed amphetamine salts (triple-bead MAS), an investigational treatment for attention-deficit/hyperactivity disorder, seems to improve ADHD symptoms in adolescents relative to placebo and demonstrates efficacy throughout a 16-hour treatment period, according to Phase II findings.

...[more] Locked

Guanfacine XR does not affect daytime sleepiness, increases evening sleepiness in children, adolescents with ADHD, safety analysis shows

Friday, October 26, 2007 | Comments

Phase II data confirm the safety profile of guanfacine extended release (XR) in children and adolescents with attention-deficit/hyperactivity disorder and suggest that the drug may increase evening sleepiness in these patients, but it does not increase daytime sleepiness in the classroom.

The current analysis was ...[more] Locked

OROS methylphenidate safely treats adult ADHD, trials show

Tuesday, October 30, 2007 | Comments

OROS methylphenidate is a safe and effective treatment for adult attention-deficit/hyperactivity disorder, according to an analysis of interim data from a long-term, open-label safety trial and data from a randomized, placebo-controlled, dose-titration study.

In the open-label safety study, OROS methylphenidate was ...[more] Locked

Research suggests atomoxetine does not increase smoking in adult smokers with ADHD, but smoking status may predict response to treatment

Tuesday, October 30, 2007 | Comments

Among adult smokers with attention-deficit/hyperactivity disorder, atomoxetine does not increase cigarette smoking, according to an analysis of Phase IV data. Additional findings suggest smoking status may affect the likelihood of treatment response in adults with ADHD.

The double-blind study included 218 adults aged 18 ...[more] Locked

Choosing best therapy for ADHD difficult, requires consideration of several factors

Tuesday, October 30, 2007 | Comments

Clinicians encounter several challenges when selecting which treatment may be optimal for patients with attention-deficit/hyperactivity disorder, but more research and new approaches could provide some guidance, according to several experts.

"I think what we want to highlight is that there are multiple factors that go ...[more] Locked

Dexmethylphenidate extended release at daily doses as high as 30 mg yields improvements in teacher-rated reports of children with ADHD

Monday, October 29, 2007 | Comments

Dexmethylphenidate extended release is effective in treating children with attention-deficit/hyperactivity disorder, according to the results of a double-blind, fixed-dose titration trial.

Researchers randomized 253 pediatric patients aged 6 to 12 years with ADHD to 1 of 4 treatment arms.  Following a washout period, ...[more] Locked

OROS methylphenidate safely treats adult ADHD, trials show

Tuesday, October 30, 2007 | Comments

OROS methylphenidate is a safe and effective treatment for adult attention-deficit/hyperactivity disorder, according to an analysis of interim data from a long-term, open-label safety trial and data from a randomized, placebo-controlled, dose-titration study.

In the open-label safety study, OROS methylphenidate was ...[more] Locked

Guanfacine XR does not affect daytime sleepiness, increases evening sleepiness in children, adolescents with ADHD, safety analysis shows

Friday, October 26, 2007 | Comments

Phase II data confirm the safety profile of guanfacine extended release (XR) in children and adolescents with attention-deficit/hyperactivity disorder and suggest that the drug may increase evening sleepiness in these patients, but it does not increase daytime sleepiness in the classroom.

The current analysis was ...[more] Locked

Choosing best therapy for ADHD difficult, requires consideration of several factors

Tuesday, October 30, 2007 | Comments

Clinicians encounter several challenges when selecting which treatment may be optimal for patients with attention-deficit/hyperactivity disorder, but more research and new approaches could provide some guidance, according to several experts.

"I think what we want to highlight is that there are multiple factors that go ...[more] Locked

Research suggests atomoxetine does not increase smoking in adult smokers with ADHD, but smoking status may predict response to treatment

Tuesday, October 30, 2007 | Comments

Among adult smokers with attention-deficit/hyperactivity disorder, atomoxetine does not increase cigarette smoking, according to an analysis of Phase IV data. Additional findings suggest smoking status may affect the likelihood of treatment response in adults with ADHD.

The double-blind study included 218 adults aged 18 ...[more] Locked

Dexmethylphenidate extended release at daily doses as high as 30 mg yields improvements in teacher-rated reports of children with ADHD

Monday, October 29, 2007 | Comments

Dexmethylphenidate extended release is effective in treating children with attention-deficit/hyperactivity disorder, according to the results of a double-blind, fixed-dose titration trial.

Researchers randomized 253 pediatric patients aged 6 to 12 years with ADHD to 1 of 4 treatment arms.  Following a washout period, ...[more] Locked



  1. No articles have been read
  1. No articles have been emailed
Videos